8-K Announcements
6Material company update
May 7, 2026·SEC
Material company update
Mar 30, 2026·SEC
Material company update
Feb 11, 2026·SEC
Neumora Therapeutics, Inc. Common Stock(NMRA)Earnings, Financials & Key Ratios
NMRA•NASDAQ
Price updated Jun 11, 2026
AboutNeumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders. In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.Show more
- Revenue$0
- EBITDA-$241M+8.3%
- Net Income-$237M+2.8%
- EPS (Diluted)-1.45+5.2%
- ROE-121.21%-88.0%
- ROIC-527.41%-229.7%
- Debt/Equity0.00-28.9%
- Interest Coverage-72.56
NMRA Key Insights
Neumora Therapeutics, Inc. Common Stock (NMRA) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
✗Weaknesses
- ✗Profits declining 19.0% over 5 years
- ✗Weak Piotroski F-Score: 2/9
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when NMRA posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
NMRA Price & Volume
Neumora Therapeutics, Inc. Common Stock (NMRA) stock price & volume — 10-year historical chart
Loading chart...
NMRA Growth Metrics
Neumora Therapeutics, Inc. Common Stock (NMRA) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM13.82%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM17.39%
Return on Capital
10 Years-64.15%
5 Years-66.85%
3 Years-73.6%
Last Year-108.22%
NMRA Recent Earnings
Neumora Therapeutics, Inc. Common Stock (NMRA) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 4/12 qtrs (36%)
Q2 2026Latest
May 7, 2026EPS
$0.30
Est $0.32
+6.3%
Revenue
—
Q2 2026
Mar 16, 2026EPS
$0.35
Est $0.34
-2.9%
Revenue
—
Q4 2025
Nov 6, 2025EPS
$0.35
Est $0.34
-2.9%
Revenue
—
Q3 2025
Aug 6, 2025EPS
$0.33
Est $0.38
+13.2%
Revenue
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $0.30vs $0.32+6.3% | — |
| Q2 2026 | Mar 16, 2026 | $0.35vs $0.34-2.9% | — |
| Q4 2025 | Nov 6, 2025 | $0.35vs $0.34-2.9% | — |
| Q3 2025 | Aug 6, 2025 | $0.33vs $0.38+13.2% | — |
Based on last 12 quarters of dataView full earnings history →
NMRA Peer Comparison
Neumora Therapeutics, Inc. Common Stock (NMRA) competitors in Neuroscience and Psychiatry Therapies — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 ACAD | 3.66B | 21.39 | 9.34 | 11.87% | 34.3% | 35.65% | 0.04 | |
 INVA | 1.66B | 22.44 | 6.80 | 18.52% | 118.91% | 47.59% | 0.23 | |
 AXSM | 13.06B | 253.77 | -68.96 | 65.55% | -26.59% | -260.01% | 2.73 | |
 PRAX | 7.16B | 247.98 | -18.40 | -100% | -43.02% | 0.00 | ||
 PTCT | 6.2B | 74.71 | 9.60 | 114.51% | -22.58% | |||
 NRXP | 67.76M | 3.92 | -2.93 | -10.7% | ||||
 ALTO | 436.7M | 5.65 | 35.31 | -4.9% | 3.16% | 12.53% | 0.40 | |
 MNMD | 2.04B | 20.69 | -10.04 | -102.48% |
Compare NMRA vs Peers
Neumora Therapeutics, Inc. Common Stock (NMRA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
NMRA Income Statement
Neumora Therapeutics, Inc. Common Stock (NMRA) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Revenue Growth % | - | - | - | - | - | - | - |
Cost of Goods Sold | 0 | 0 | 0 | 668K | 0 | 5M | 5.01M |
COGS % of Revenue | - | - | - | - | - | - | - |
Gross Profit | 0▲ 0% | 0▲ 0% | 0▲ 0% | -668K▲ 0% | 0▲ 100.0% | -5M▲ 0% | -5.01M▲ 0% |
Gross Margin % | - | - | - | - | - | - | - |
Gross Profit Growth % | - | - | - | - | 100% | - | - |
Operating Expenses | 95.52M | 237.32M | 135.87M | 187.53M | 263.46M | 236.16M | 218.08M |
OpEx % of Revenue | - | - | - | - | - | - | - |
Selling, General & Admin | 8.39M | 24.55M | 31.12M | 44.81M | 62.54M | 60.09M | 55.57M |
SG&A % of Revenue | - | - | - | - | - | - | - |
Research & Development | 87.13M | 212.78M | 104.75M | 142.72M | 200.93M | 176.06M | 162.51M |
R&D % of Revenue | - | - | - | - | - | - | - |
Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Operating Income | -95.52M▲ 0% | -237.32M▼ 148.5% | -135.87M▲ 42.7% | -188.19M▼ 38.5% | -263.46M▼ 40.0% | -241.16M▲ 8.5% | -223.08M▲ 0% |
Operating Margin % | - | - | - | - | - | - | - |
Operating Income Growth % | - | -148.46% | 42.75% | -38.51% | -40% | 8.47% | - |
EBITDA | -95.41M | -236.78M | -135.28M | -187.53M | -262.83M | -240.95M | -223.03M |
EBITDA Margin % | - | - | - | - | - | - | - |
EBITDA Growth % | - | -148.17% | 42.87% | -38.62% | -40.16% | 8.33% | 18.51% |
D&A (Non-Cash Add-back) | 105K | 538K | 594K | 668K | 631K | 208K | 59K |
EBIT | -95.52M | -237.32M | -135.87M | -188.19M | -263.46M | -233.58M | -220.33M |
Net Interest Income | 0 | 0 | 4.56M | 16.61M | 19.93M | 5.13M | 1.43M |
Interest Income | 0 | 0 | 4.56M | 16.61M | 19.93M | 8.34M | 6.07M |
Interest Expense | 0 | 0 | 0 | 0 | 0 | 3.22M | 4.64M |
Other Income/Expense | -3.75M | 11K | 4.97M | -47.46M | 19.86M | 4.36M | 745K |
Pretax Income | -99.27M▲ 0% | -237.31M▼ 139.1% | -130.9M▲ 44.8% | -235.66M▼ 80.0% | -243.61M▼ 3.4% | -236.8M▲ 2.8% | -222.34M▲ 0% |
Pretax Margin % | - | - | - | - | - | - | - |
Income Tax | 0 | 0 | 0 | 268K | 178K | 130K | 55K |
Effective Tax Rate % | 0% | 0% | 0% | -0.11% | -0.07% | -0.05% | -0.02% |
Net Income | -99.27M▲ 0% | -237.31M▼ 139.1% | -130.9M▲ 44.8% | -235.93M▼ 80.2% | -243.79M▼ 3.3% | -236.93M▲ 2.8% | -222.39M▲ 0% |
Net Margin % | - | - | - | - | - | - | - |
Net Income Growth % | - | -139.05% | 44.84% | -80.23% | -3.33% | 2.81% | 13.82% |
Net Income (Continuing) | -99.27M | -237.31M | -130.9M | -235.93M | -243.79M | -236.93M | -222.39M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -0.65▲ 0% | -1.56▼ 140.0% | -0.86▲ 44.9% | -1.49▼ 73.3% | -1.53▼ 2.7% | -1.45▲ 5.2% | -1.24▲ 0% |
EPS Growth % | - | -140% | 44.87% | -73.26% | -2.68% | 5.23% | 17.39% |
EPS (Basic) | -0.65 | -1.56 | -0.86 | -1.49 | -1.53 | -1.45 | - |
Diluted Shares Outstanding | 151.95M | 151.95M | 151.95M | 158.83M | 159.38M | 163.39M | 179.87M |
Basic Shares Outstanding | 151.95M | 151.95M | 151.95M | 158.83M | 159.38M | 163.39M | 179.87M |
Dividend Payout Ratio | - | - | - | - | - | - | - |
NMRA Balance Sheet
Neumora Therapeutics, Inc. Common Stock (NMRA) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|
Total Current Assets | 193.84M | 415.6M | 387.95M | 478.28M | 314.06M | 190.54M | 153.43M |
Cash & Short-Term Investments | 191.98M | 409.25M | 371.88M | 453.98M | 307.58M | 182.53M | 147.07M |
Cash Only | 191.98M | 409.25M | 240.94M | 374.04M | 142.15M | 182.53M | 147.07M |
Short-Term Investments | 0 | 0 | 130.94M | 79.94M | 165.43M | 0 | 0 |
Accounts Receivable | 148K | 200K | 919K | 939K | 0 | 0 | 0 |
Days Sales Outstanding | - | - | - | - | - | - | - |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - |
Other Current Assets | 125K | 125K | 50K | 0 | 6.48M | 8.01M | 6.36M |
Total Non-Current Assets | 4.11M | 13.69M | 38.28M | 17.92M | 2.92M | 510K | 443K |
Property, Plant & Equipment | 3.92M | 4.04M | 10.64M | 6.86M | 2.92M | 457K | 390K |
Fixed Asset Turnover | - | - | - | - | - | - | 0.00x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 0 | 0 | 23.51M | 9.85M | 0 | 0 | 0 |
Other Non-Current Assets | 183K | 9.65M | 4.13M | 1.21M | 0 | 53K | 53K |
Total Assets | 197.95M▲ 0% | 429.3M▲ 116.9% | 426.23M▼ 0.7% | 496.19M▲ 16.4% | 316.97M▼ 36.1% | 191.05M▼ 39.7% | 153.88M▲ 0% |
Asset Turnover | - | - | - | - | - | - | 0.00x |
Asset Growth % | - | 116.88% | -0.71% | 16.41% | -36.12% | -39.73% | -174.01% |
Total Current Liabilities | 9.37M | 23.28M | 23.7M | 25.11M | 29.89M | 32.45M | 30.11M |
Accounts Payable | 2.4M | 1.64M | 7.15M | 337K | 3.31M | 3.38M | 5.06M |
Days Payables Outstanding | - | - | - | 184.14 | - | 246.67 | 175.45 |
Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 284K | 291K |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 4.13M | 8.13M | 10.04M | 10.15M | 10.11M | 28.79M | 24.77M |
Current Ratio | 20.69x | 17.85x | 16.37x | 19.05x | 10.51x | 5.87x | 5.09x |
Quick Ratio | 20.69x | 17.85x | 16.37x | 19.05x | 10.51x | 5.87x | 5.09x |
Cash Conversion Cycle | - | - | - | - | - | - | - |
Total Non-Current Liabilities | 282.96M | 731.24M | 849.39M | 2.01M | 22K | 54.73M | 53.08M |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 193K | 119K |
Capital Lease Obligations | 1.28M | 996K | 5.07M | 1.85M | 0 | 0 | 339K |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 281.68M | 730.24M | 844.32M | 155K | 22K | 54.53M | 52.96M |
Total Liabilities | 292.33M | 754.52M | 873.08M | 27.12M | 29.91M | 87.18M | 83.2M |
Total Debt | 2.04M | 2.05M | 8.44M | 5.23M | 1.85M | 477K | 410K |
Net Debt | -189.93M | -407.19M | -232.5M | -368.81M | -140.29M | -182.05M | -146.66M |
Debt / Equity | - | - | - | 0.01x | 0.01x | 0.00x | 0.01x |
Debt / EBITDA | - | - | - | - | - | - | -0.00x |
Net Debt / EBITDA | - | - | - | - | - | - | 0.66x |
Interest Coverage | - | - | - | - | - | -72.56x | -47.51x |
Total Equity | -94.38M▲ 0% | -325.22M▼ 244.6% | -446.85M▼ 37.4% | 469.08M▲ 205.0% | 287.06M▼ 38.8% | 103.87M▼ 63.8% | 70.68M▲ 0% |
Equity Growth % | - | -244.57% | -37.4% | 204.97% | -38.8% | -63.82% | -243.69% |
Book Value per Share | -0.62 | -2.14 | -2.94 | 2.95 | 1.80 | 0.64 | 0.39 |
Total Shareholders' Equity | -94.38M | -325.22M | -446.85M | 469.08M | 287.06M | 103.87M | 70.68M |
Common Stock | 13K | 3K | 3K | 16K | 16K | 17K | 18K |
Retained Earnings | -99.29M | -336.61M | -467.51M | -703.43M | -947.22M | -1.18B | -1.24B |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 0 | 0 | -774K | -76K | 62K | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
NMRA Cash Flow Statement
Neumora Therapeutics, Inc. Common Stock (NMRA) cash flow — operating, investing & free cash flow history
| Metric | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|
Cash from Operations | -26.76M | -75.42M | -114.9M | -163.28M | -182.94M | -206.44M | -193.4M |
Operating CF Margin % | - | - | - | - | - | - | - |
Operating CF Growth % | - | -181.84% | -52.34% | -42.11% | -12.04% | -12.85% | -5.91% |
Net Income | -99.27M | -237.31M | -130.9M | -235.93M | -243.79M | -236.93M | -222.39M |
Depreciation & Amortization | 105K | 538K | 594K | 668K | 0 | 208K | 59K |
Stock-Based Compensation | 1.68M | 4.27M | 8.3M | 17.24M | 39.99M | 29.88M | 27.96M |
Deferred Taxes | 3.08M | -53K | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 70.77M | 158.09M | 14.06M | 63.64M | -1.77M | 841K | 1.66M |
Working Capital Changes | -3.12M | -961K | -6.95M | -8.9M | 22.64M | -437K | -677K |
Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | -4.67M | -759K | -1.25M | -581K | 2.87M | 71K | 4M |
Cash from Investing | -11.24M | -817K | -168.01M | 64.39M | -70.56M | 168.52M | 124.43M |
Capital Expenditures | -1.3M | -817K | -511K | -117K | 0 | 0 | 16K |
CapEx % of Revenue | - | - | - | - | - | - | - |
Acquisitions | 0 | 0 | 0 | 0 | -775K | 0 | 155K |
Investments | - | - | - | - | - | - | - |
Other Investing | -9.94M | 0 | -13M | -4.59M | 0 | 3.15M | 1.15M |
Cash from Financing | 230.1M | 293.51M | 115.74M | 231.94M | 21.6M | 77.09M | 87.96M |
Debt Issued (Net) | 55.91M | 0 | 0 | 0 | 0 | 57.16M | 57.16M |
Equity Issued (Net) | 174.19M | 292.14M | 112.22M | 232.88M | 13.69M | 19.93M | 11.15M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | -2K | 0 | 0 | -491K | 0 | 0 | 0 |
Other Financing | 0 | 1.37M | 3.53M | -948K | 7.91M | 0 | 19.65M |
Net Change in Cash | 192.1M▲ 0% | 217.27M▲ 13.1% | -167.17M▼ 176.9% | 133.04M▲ 179.6% | -231.89M▼ 274.3% | 39.17M▲ 116.9% | 19M▲ 0% |
Free Cash Flow | -28.06M▲ 0% | -76.24M▼ 171.7% | -115.41M▼ 51.4% | -163.4M▼ 41.6% | -182.94M▼ 12.0% | -206.44M▼ 12.8% | -193.4M▲ 0% |
FCF Margin % | - | - | - | - | - | - | - |
FCF Growth % | - | -171.69% | -51.38% | -41.58% | -11.96% | -12.85% | 3.03% |
FCF per Share | -0.18 | -0.50 | -0.76 | -1.03 | -1.15 | -1.26 | -1.08 |
FCF Conversion (FCF/Net Income) | 0.27x | 0.32x | 0.88x | 0.69x | 0.75x | 0.87x | 0.87x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 1.5M | 833K |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 323K | 323K |
NMRA Key Ratios
Neumora Therapeutics, Inc. Common Stock (NMRA) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | - | -2122.96% | -64.48% | -121.21% | -181.7% |
| Return on Invested Capital (ROIC) | - | - | -140.77% | -159.97% | -527.41% | 926.51% |
| Debt / Equity | - | - | 0.01x | 0.01x | 0.00x | 0.01x |
| Interest Coverage | - | - | - | - | -72.56x | -47.51x |
| FCF Conversion | 0.32x | 0.88x | 0.69x | 0.75x | 0.87x | 0.87x |
Related:NMRA Dividend History·NMRA Revenue History·NMRA Price History·NMRA P/E History·NMRA Financial Ratios·NMRA Institutional Holders
NMRA SEC Filings & Documents
Neumora Therapeutics, Inc. Common Stock (NMRA) SEC filings — annual & quarterly reports (10-K, 10-Q)
NMRA Frequently Asked Questions
Neumora Therapeutics, Inc. Common Stock (NMRA) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Neumora Therapeutics, Inc. Common Stock (NMRA) grew revenue by 0.0% over the past year. Growth has been modest.
Neumora Therapeutics, Inc. Common Stock (NMRA) reported a net loss of $222.4M for fiscal year 2025.
Dividend & Returns
Neumora Therapeutics, Inc. Common Stock (NMRA) has a return on equity (ROE) of -121.2%. Negative ROE indicates the company is unprofitable.
Neumora Therapeutics, Inc. Common Stock (NMRA) had negative free cash flow of $193.4M in fiscal year 2025, likely due to heavy capital investments.